BioSpace News Archive

David Benshoof Klein is CEO and founder of Click Therapeutics. He was recognized by Goldman Sachs as one of the 100 most intriguing entrepreneurs of 2019, and was honored as a PharmaVoice 100 recipient in October of 2024.

Young Woman Standing In Front Of Exit Door. Full Length, Vector, Illustration, Flat Design, Character.

Layoffs

Viracta Therapeutics Cuts 42% of Staff as Part of Resource Reprioritization

Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.

November 7, 2024

·

2 min read

·

Angela Gabriel

Whitchurch-Stouffville, On, Canada: - May 30, 2021: Teva Canada Ltd facility in Whitchurch-Stouffville, On, Canada. Teva Pharmaceutical Industries Ltd. is an Israeli pharmaceutical company.

Earnings

Teva Reports Strong Generics Demand in Q3, Expects Higher 2024 Revenue

Driven by copycat versions of Bristol Myers Squibb’s Revlimid and Novo Nordisk’s Victoza, Teva’s generics business was again a top-performer in the third quarter, with U.S. sales growing 30% and bringing in $1.1 billion in sales.

November 7, 2024

·

2 min read

·

Tristan Manalac

Earnings

Sarepta Halts Development of Next-Gen DMD Drug, Reports Robust Elevidys Sales

The investigational therapy, vesleteplirsen, had been positioned as an updated version of Sarepta’s original exon 51-skipping Duchenne muscular dystrophy drug Exondys 51.

November 7, 2024

·

2 min read

·

Heather McKenzie

Business

Investing in AI: Benefits, Regulatory Challenges

In this episode of Denatured, BioSpace’s Head of Insights Lori and guests from Teva Pharmaceuticals and TOWER Capital discuss the opportunities, regulatory challenges and uncertainty surrounding AI.

November 7, 2024

·

1 min read

·

Lori Ellis

Check mate. hand of businessman moving chess figure Trendy 3d collage in magazine style. Contemporary art. Modern design

GLP-1

While Lilly Blames Wholesalers for Slow GLP-1 Sales, Novo’s Rival Medicine Is Flowing

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week. But Eli Lilly reported slower than expected sales in the third quarter due to wholesaler destocking.

November 7, 2024

·

3 min read

·

Annalee Armstrong

Pictured: Facade of Moderna's building in Massachusetts

Earnings

Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday note to investors said sales of the company’s respiratory syncytial virus vaccine mRESVIA was significantly lower than expected.

November 7, 2024

·

3 min read

·

Tristan Manalac

Job Trends

2024 Q3 Job Market Report: Biopharma Professionals Face Heavy Competition for Fewer Jobs

Year-over-year BioSpace data shows there are fewer job postings live on the website and far more competition for them.

November 7, 2024

·

3 min read

·

Angela Gabriel

Gilead sign at headquarters. FDA will reportedly authorize use of remdesivir developed by biopharmaceutical company Gilead Sciences for Covid-19 treatment - Foster City, California, USA - 2020

Earnings

Gilead Beats Q3 Expectations Fueled by HIV Drug Sales, Raises Full-Year Guidance

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and “steady,” while noting the company continues to demonstrate “reliable strength” in its human immunodeficiency virus business.

November 7, 2024

·

3 min read

·

Tristan Manalac

Press Releases

Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3

November 7, 2024

·

2 min read